The present invention relates to novel substituted piperidine and morpholine compounds of formula (I)whereinX is O or CF2;R1 and R2 are independently selected from the group consisting of hydrogen, CH2OH, CH2F, CHF2, cyclopropyl, or -C≡CH with the proviso that when one of R1 and R2 is CH2OH, CH2F, CHF2, cyclopropyl or -C≡CH, then the other of R1 or R2 is hydrogen, having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.